TScan Therapeutics just cut 75% of its workforce, and the timing makes the cut particularly stark: the company dosed its first patient in the ALLOHA-2 Phase 3 trial on July 29, 2026, roughly five weeks before the September 2 decision to pause enrollment entirely. A Phase 3 trial in AML and MDS patients at high relapse risk after allogeneic hematopoietic cell transplantation, barely open, is now on ice.
The pivot is blunt. TScan is redirecting its remaining resources toward preclinical development of an in vivo solid tumor program, abandoning the clinical-stage cell therapy infrastructure that presumably consumed most of the payroll now being eliminated. For a company that raised over $48 million through its Series B alone, with backers including Bessemer Venture Partners, GV, and Novartis Venture Fund, this is not a trimming. It is a near-total operational reset. The people who ran site monitoring, regulatory affairs, and clinical operations for TSC-101 across the ALLOHA-2 study are largely gone.
What this means clinically is real and underappreciated. Post-transplant relapse in AML and MDS remains a setting where durable options are limited and where a randomized Phase 3 dataset would carry genuine weight. TSC-101 was designed to address residual disease in that window, and the trial had cleared the hardest early hurdle: first patient dosed. Pausing at that moment, rather than after an interim futility signal, signals a resource and capital problem rather than a data problem. That distinction matters to anyone tracking the competitive landscape, because it leaves the scientific hypothesis largely untested rather than discredited.
The single thing worth watching now is whether TScan discloses a partner, acquirer, or out-licensing arrangement for TSC-101 in the coming weeks. A 75% workforce reduction with a parallel pivot to preclinical work often precedes an asset sale rather than a clean shutdown, and the ALLOHA-2 trial infrastructure, however early, has enrollment-ready sites and a freshly activated IND. That infrastructure has value to any larger player looking to re-enter the post-HCT relapse prevention space without building from scratch.
Source link: https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
